Samlyn Capital, LLC Clovis Oncology, Inc. Transaction History

Samlyn Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $3.75 Million - $14.6 Million	-953,711 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $7.47 Million - $15 Million	582,871 Added 157.18%	953,711 $14.2 Million
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $11.2 Million - $19.2 Million	-634,397 Reduced 63.11%	370,840 $9.2 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $11.7 Million - $32.8 Million	1,005,237 New	1,005,237 $18.1 Million
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $13 Million - $19.2 Million	-308,119 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $18.9 Million - $25.5 Million	-376,417 Reduced 54.99%	308,119 $16.3 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $9.36 Million - $13.7 Million	162,191 Added 31.05%	684,536 $46.5 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $35.1 Million - $44.3 Million	522,345	522,345 $43 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.